Friday, July 10, 2026

Drug profile · INN

nerandomilast

nerandomilast (JASCAYD) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: unknown
US status approved
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — nerandomilast
US status
approved
Class
Route
ORAL
Patents
0
Programs
4
Data quality
0.84

Quick answer

nerandomilast (JASCAYD) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN nerandomilast
Brand JASCAYD
Route ORAL
Formulation TABLET

Approval history

Authority Status Date
FDA approved
EMA unknown

Recent coverage

Pipeline programs

  1. 1305-0046 Phase 3 · Boehringer Ingelheim · Systemic Autoimmune Rheumatic Diseases associated Interstiti
  2. 1305-0113 Phase 1 · Boehringer Ingelheim · Healthy volunteer trial
  3. 1305-0119 Phase 1 · Boehringer Ingelheim · Healthy volunteer trial
  4. BI 1015550, NERANDOMILAST Phase 1 · Boehringer Ingelheim · Healthy volunteer trial

Frequently asked questions

What is nerandomilast?

nerandomilast (JASCAYD) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for nerandomilast?

JASCAYD is a marketed brand name for nerandomilast. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of nerandomilast?

nerandomilast has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.